Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature

Research output: Contribution to journalReviewResearchpeer-review

  1. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cost-effectiveness targeting CLL

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Declining mortality rates in children admitted to ICU following HCT

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Health screening among children newly granted asylum in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Chimerism analysis following hematopoietic stem cell transplantation (HSCT) for leukemia is routinely applied in parallel with quantification of minimal residual disease (MRD) to identify imminent relapse. In the past decades, new methods with a lower limit of detection compared to standard methods have been developed, so-called microchimerism analysis. Microchimerism analysis is fast, simple, applicable across pre-HSCT disease-type and can be applied on peripheral blood allowing frequent testing during follow-up. Monitoring of microchimerism in blood could replace repeated bone marrow analysis for MRD and allow earlier detection of imminent relapse or graft failure. Clinical studies in single center cohorts have shown conflicting but promising results. There is currently no consensus on the interpretation of microchimerism analysis and heterogeneity of studies remains a major obstacle for inter-study comparisons and meta-analysis in this field. We have conducted a systematic review of studies investigating associations between microchimerism and relapse of leukemia post-HSCT. We summarize current evidence and provide suggestions for future research.

Original languageEnglish
JournalBlood
Volume44
Pages (from-to)100673
ISSN0006-4971
DOIs
Publication statusPublished - Nov 2020

    Research areas

  • Allogeneic hematopoietic cell transplantation, Childhood leukemia, Chimerism, Microchimerism, Relapse

ID: 61695986